Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetic upregulation of Schlafen11 renders 
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
Nakata S, Murai J, Okada M, Takahashi H, Findlay TH, Malebranche K, Parthasarathy A, Miyashita S, Gabdulkhaev R, Benkimoun I, Druillennec S, Chabi S, Hawkins E, Miyahara H, Tateishi K, Yamashita S, Yamada S, Saito T, On J, Watanabe J, Tsukamoto Y, Yoshimura J, Oishi M, Nakano T, Imamura M, Imai C, Yamamoto T, Takeshima H, Sasaki AT, Rodriguez FJ, Nobusawa S, Varlet P, Pouponnot C, Osuka S, Pommier Y, Kakita A, Fujii Y, Raabe EH, Eberhart CG, Natsumeda M. Nakata S, et al. Among authors: oishi m. Neuro Oncol. 2023 May 4;25(5):899-912. doi: 10.1093/neuonc/noac243. Neuro Oncol. 2023. PMID: 36273330 Free PMC article.
GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma.
Natsumeda M, Miyahara H, Yoshimura J, Nakata S, Nozawa T, Ito J, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Oishi M, Hirato J, Wataya T, Ahsan S, Tateishi K, Yamamoto T, Rodriguez FJ, Takahashi H, Hovestadt V, Suva ML, Taylor MD, Eberhart CG, Fujii Y, Kakita A. Natsumeda M, et al. Among authors: oishi m. J Neuropathol Exp Neurol. 2021 Jan 20;80(2):129-136. doi: 10.1093/jnen/nlaa141. J Neuropathol Exp Neurol. 2021. PMID: 33249504
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Abe H, Natsumeda M, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Yoshimura J, Oishi M, Fujii Y. Abe H, et al. Among authors: oishi m. Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):290-295. doi: 10.2176/nmc.ra.2018-0044. Epub 2018 May 31. Neurol Med Chir (Tokyo). 2018. PMID: 29848907 Free PMC article. Review.
EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma.
Nozawa T, Okada M, Natsumeda M, Eda T, Abe H, Tsukamoto Y, Okamoto K, Oishi M, Takahashi H, Fujii Y, Kakita A. Nozawa T, et al. Among authors: oishi m. Neurol Med Chir (Tokyo). 2019 Mar 15;59(3):89-97. doi: 10.2176/nmc.oa.2018-0078. Epub 2019 Feb 21. Neurol Med Chir (Tokyo). 2019. PMID: 30787232 Free PMC article.
Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features.
Natsumeda M, Chang M, Gabdulkhaev R, Takahashi H, Tsukamoto Y, Kanemaru Y, Okada M, Oishi M, Okamoto K, Rodriguez FJ, Kakita A, Fujii Y, Schreck KC. Natsumeda M, et al. Among authors: oishi m. Brain Tumor Pathol. 2021 Jul;38(3):228-233. doi: 10.1007/s10014-021-00407-0. Epub 2021 Jul 3. Brain Tumor Pathol. 2021. PMID: 34216310
Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide.
Eda T, Okada M, Ogura R, Tsukamoto Y, Kanemaru Y, Watanabe J, On J, Aoki H, Oishi M, Takei N, Fujii Y, Natsumeda M. Eda T, et al. Among authors: oishi m. Cancers (Basel). 2022 Feb 2;14(3):770. doi: 10.3390/cancers14030770. Cancers (Basel). 2022. PMID: 35159037 Free PMC article.
1,025 results